ACCESSWIRE

Historic Uranium Estimate at Marysvale Project

Share

Highlights

  • Historic Resource Estimate is of up to 2.9Mlbs U3O8 within 300-500 feet of the surface1.

  • Historic Drilling of 115 holes (102 by Phillips Minerals in the 1970s, 13 by Trigon Exploration in 2007).

  • Potential to double or triple historic estimate.

WOODLAND HILLS, CA / ACCESSWIRE / September 12, 2024 / TONOGOLD Resources Inc. (OTC PINK:TNGL) ("TONOGOLD" or the "Company") and its merger partner, JAG Minerals USA, Inc are pleased to provide an update on the historic resource estimates for their Marysvale Project, Southwestern Utah. This news release provides a detailed summary of the historic data and the future potential.

null

Figure 1: Project and Process Mill locations.

1 Proctor, P.D. (pre-2000). Private Report on the Marysvale Uranium Project. (Referenced in the NI 43-101 report by Havenstrite and Hardy, 2006)

Project Background

The Marysvale Mining District, located in Southwestern Utah, has a rich history of exploration and production. The Company currently holds 20 lode mining claims in this district, strategically positioned adjacent to the historic Central Mining Area. This area produced an estimated 1.39 million lbs. of U3O8 at an average grade of 0.22% from more than 10 mines between 1949 and 19662.

null

Figure 2: Marysvale Project over USGS deposits.

2 Geology and uranium-vanadium deposits of the La Sal quadrangle, San Juan County, Utah, and Montrose County, Colorado, Carter, W.D., and Gualtieri, J.L. USGS, PP 508, 1965

Historic Drilling

The Marysvale Mining District has a rich history of exploration:

  • Phillips Minerals (1970s): Conducted 102 drill holes across the district, providing substantial initial data on the mineralization.

  • Trigon Exploration (2007): Added 13 drill holes, which confirmed and expanded upon the data collected by Phillips Minerals.

Notable Drill Intercepts:

  • Hole 24-91: 88.0 ft @ 0.07% eU3O8 (equivalent U3O8)

  • Hole 24-105: 47.5 ft @ 0.13% eU3O8

  • Hole 24-28: 64.5 ft @ 0.09% eU3O8

  • Hole 24-20: 45.5 ft @ 0.12% eU3O8

  • Hole 30-4: 56.0 ft @ 0.07% eU3O8

null

Figure 3: Historic Drilling on Marysvale Property.

Historic Resource Estimate

The Proctor Report, prepared by Paul Dean Proctor, PhD., a professor of geology at Brigham Young University, provides a historical estimate of uranium reserves at the Marysvale Project based on drilling conducted by Phillips Uranium Company in the late 1970s and early 1980s. Although this estimate predates National Instrument 43-101 standards and current US SEC Regulation S-K reporting standard and is not compliant with modern requirements, it offers valuable insights into the potential size and grade of uranium deposits at the site.

Historical Estimate of Uranium Reserves

  • Total Estimated Reserves: At least 2.9 million lbs. U3O8.

  • Grade and Tonnage:

    • 0.75 million tons at 0.075% U3O8 (1.125 million lbs. U3O8).

    • 3.0 million tons at 0.03% U3O8 (1.8 million lbs. U3O8).

  • Depth: Mineralization occurs within 300-500 feet of the surface.

Potential for Expansion

Proctor suggests that additional potential uranium ore exists on the property, which could double or triple the current reserves. This is based on gamma ray (eU) anomalies detected over a large alteration system along a major northwest-trending fault zone.

Drilling Data

The Proctor Report references drill intercepts from Phillips Uranium Company's drilling program, including intervals such as "25 feet of 0.22% and 15 feet of 0.50% U3O8." These intercepts indicate significant primary uranium mineralization below the zone of secondary minerals.

Survey Data

A surface radiometric survey conducted by Phillips in 1981 detected areas of anomalous radiation (>200 counts per second), although the correlation with argillic alteration zones was imperfect. Locations of these anomalies remain unknown, but they indicate potential targets for further exploration.

Conclusion

The Proctor Report provides a detailed historical perspective on the Marysvale Uranium Project, highlighting significant uranium mineralization and the potential for resource expansion. Although the data predates modern standards, it underscores the importance of further exploration to fully realize the property's potential. The Company has not yet independently validated or confirmed the historic resource estimates under current reporting and disclosure standards.

Reference:

Proctor, P.D. (pre-2000). Private Report on the Marysvale Uranium Project. (Referenced in the NI 43-101 report by Havenstrite and Hardy, 2006)​

Geology and Mineralization

Favorable Geology: The property lies within the Cenozoic Marysvale volcanic field, astride the transition zone between the Colorado Plateau and the Great Basin.

null

Figure 4: Marysvale Geology with interpreted mineralization from historic drilling.

Mineralization Depth: Uranium mineralization occurs from the surface to a depth of approximately 500 ft in strongly clay-altered rhyolitic volcanics.

Structural Control: Mineralization is structurally controlled within fault blocks, making it favorable for both surface and underground mining methods.

Mineralization remains open-ended, suggesting further potential for resource expansion.

null

Figure 5: Outcrop sample SL06 field photo (RS-125 unit returned 45,200 cps).

null

Figure 6: Using the RS-125 to get elevated cps values on the tree for comparison against the surrounding counts.

Future Plan

Enhance the project's value by advancing the understanding and resource base through targeted drilling and gamma logging of 15-20 holes with geochemical analysis to define disequilibrium and test extensions. Update the NI 43-101 Technical Report with these findings, and strategically focus exploration efforts on delineating and expanding the known mineral inventory, emphasizing bulk tonnage supergene deposits and higher-grade vein deposits.

TONOGOLD CEO William Hunter stated: "During the 2023 geological field season JAG Minerals USA, Inc. was active in expanding its Uranium and Vanadium claims in Wyoming, Utah and Colorado. Specifically focused on claims that have detailed historic Uranium data and / or published resources open for potential expansion. Further, the areas need access to mills to process the mined Uranium products. This development is very positive to the combined Company and will be very positive for the Company in the recently announced transaction JAG Minerals USA, Inc.

Disclaimer Regarding Historic Estimates

The historical resource estimates provided in this release are based on data obtained and prepared by previous operators and have not been verified by either the Company or a qualified person as defined by NI 43-101 or in US SEC Regulation S-K and the rules promulgated thereunder regarding the reporting of historical resource estimates. These estimates are considered historical and do not conform to current NI 43-101 standards or to current US SEC reporting standards. A qualified person has not done sufficient work to classify the historical estimates as current mineral resources or mineral reserves, and the Company is not treating these historical estimates as current mineral resources or mineral reserves. Further work, including drilling and analysis, is required to verify these historical estimates and upgrade them to meet NI 43-101 standards and current US SEC reporting standards.

This estimate was made prior to implementation of National Instrument 43-101 standards and prior to the implementation of current US SEC Regulation S-K and related reporting standards, and does not qualify as a resource or reserve, and thus, the historical estimate should not be relied upon.

Qualified person

Mr Andrew Hawker, BSc. Geol, MAIG, is a member of the Australasian Institute Geoscientists, is a consultant to JAG Minerals USA, Inc. and is a Qualified Person as defined in National Instrument 43-101. Mr Hawker is in charge of exploration programs and has reviewed and approved the technical information contained in this news release.

Enquiries
For further information, please contact:
William Hunter
Interim CEO Tonogold Resources Inc
M: +1 203 856 7285
E: bhunter@tonogold.com

SOURCE: Tonogold Resources, Inc.



View the original press release on accesswire.com

Tonogold Resources, Inc.

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

“Bogotá Your Home”: A Showcase of Bogotá’s New Image at COP1629.10.2024 14:30:00 CET | Press release

BOGOTÁ, COLOMBIA / ACCESSWIRE / October 29, 2024 / "Bogotá tu casa" - "Bogotá Your Home", a campaign led by the District Institute of Tourism in collaboration with the Bogotá Chamber of Commerce and Invest in Bogotá, was showcased at COP16 to hundreds of visitors. The campaign highlighted the capital's key attributes and opportunities for tourists, entrepreneurs, and investors. "As Invest in Bogotá, we supported this activation to show the world why Bogotá is a city full of opportunities for businesspeople, investors, and global-scale events. We look forward to guiding international decision-makers in exploring the city's investment opportunities as a platform for business expansion and growth", said Isabella Muñoz. "Bogotá Your Home," the new campaign by the Bogotá District Institute of Tourism, the Bogotá Chamber of Commerce, and Invest in Bogotá, was promoted at COP16. The event took place at the House of Bogotá and the Bogotá Chamber of Commerce at Bulevar del Río in Cali, the host

Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio29.10.2024 08:00:00 CET | Press release

FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. The company was founded as a spin-out of the University of Edinburgh, Scotland, together with lead investor Epidarex Capital, a leading early-stage transatlantic venture fund, along with IP Group, and Scottish Enterprise. Effective immediately, Kynos Therapeutics will be integrated into the Falk Group. Dr. Falk Pharma Dr. Falk Pharma Logo Kynos Therapeutics' lead investigational asset is KNS366, a highly potent and selective first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase (KMO). In a Phase I clinical trial, KNS366 was shown to be safe and well-tolerated at multiple doses. The compound also led to a dose-dependent inhibition of the enzyme KMO and modulation of its downs

Polaris Renewable Energy Announces Acquisition Transaction in Puerto Rico29.10.2024 07:50:00 CET | Press release

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that it has entered into an Equity Capital Contribution Agreement ("ECCA") with respect to Punta Lima Wind Farm LLC (a wholly owned subsidiary of Santander Bank N.A. -"Santander"-). The project is an operating onshore wind farm called Punta Lima Wind Farm ("PLWF" or the "Project") with a nameplate capacity of 26.0 MW's located in the Municipality of Naguabo, Puerto Rico. The Project was re-constructed and recommissioned by Santander and has a 20-year power purchase agreement ("PPA") in place with Puerto Rico Electric Power Authority (PREPA) terminating in March 2044. The transaction is being completed using a tax-equity structure which will result in Polaris becoming the manager and operator of the Project with a controlling equity interest and Santander retaining a tax equity interest in the Project. the transaction is subject to customary closing

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases29.10.2024 03:05:00 CET | Press release

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. The patents are 100% owned by BioNxt. Subject to the international Patent Cooperation Treaty ("PCT"), the European Patent Office ("EPO") issued a positive International Preliminary Report on Patentability ("IPRP"), announced by the Company on September 9, 2024. The EPO accepted the Company's claim that the patent family was new, useful, and non-obvious, satisfying the requirements for patentability. Based on the report's findings, BioNxt is advancing its patent protection process to national level filings in the following international jurisdictions: Independent filing nations: Australia (AU), Canada (CA), New Zealand (NZ), USA (US), Japan

New CEO Commits to Strengthening OMP’s Leadership in Advanced Supply Chain Planning29.10.2024 02:00:00 CET | Press release

ANTWERPEN, BELGIUM / ACCESSWIRE / October 29, 2024 / In a leadership transition at the Antwerp-based supply chain specialists, Anita Van Looveren will step into her new role as Chairwoman of the Board of Directors on November 1, after nearly 25 years in the CEO role and almost 40 years with the company. Paul Vanvuchelen, Global Delivery Lead, will succeed her as CEO, beginning a new chapter for OMP with a focus on strengthening its leadership in advanced supply chain planning. In her new position, Anita Van Looveren will continue to work closely with Paul Vanvuchelen, offering strategic guidance and support. Anita Van Looveren and Paul Vanvuchelen Under the stewardship of company founder Georges Schepens and long-time CEO Anita Van Looveren, OMP has grown into a global leader inadvanced supply chain planning. Since its inception in 1985, OMP has built a strong reputation by working with an expanding portfolio of customers, including innovative startups and blue-chip giants. OMP has hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye